Nanomedicine and Immunotherapy for Cancers

  • Navas A
  • Doreswamy N
  • Joseph Francis P
N/ACitations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Nanomedicine contributes to cancer therapeutics in several ways, harnessing some of the remarkable properties of nanomaterials to target tumor cells with increasing specificity. Nano-scale therapeutic strategies enable the simultaneous transport of hydrophilic and hydrophobic drugs across physical and physiological barriers like the blood-brain barrier. Alternative routes of drug administration, such as the intranasal route, have become viable, with more promising therapies for highly lethal tumors like glioblastomas. Cancer nanomedicine allows increased solubility and bioavailability of anti-cancer drugs, reducing their toxicity. Multi-drug delivery systems such as dendrimers, noble metal nanoparticle drug delivery systems, nanoparticle-based theranostics, and nano-biomarkers may well bring about a sea change in cancer therapeutics. This review presents an overview of the scope of cancer nanomedicine, including immunotherapy for cancer.

Cite

CITATION STYLE

APA

Navas, A. A., Doreswamy, N., & Joseph Francis, P. J. (2020). Nanomedicine and Immunotherapy for Cancers. European Journal of Medical and Health Sciences, 2(5). https://doi.org/10.24018/ejmed.2020.2.5.482

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free